183 related articles for article (PubMed ID: 25622075)
21. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
[TBL] [Abstract][Full Text] [Related]
22. Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78.
Machihara K; Tanaka H; Hayashi Y; Murakami I; Namba T
Biochem Biophys Res Commun; 2017 Oct; 492(1):33-40. PubMed ID: 28811106
[TBL] [Abstract][Full Text] [Related]
23. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
[TBL] [Abstract][Full Text] [Related]
24. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Tang TC; Man S; Lee CR; Xu P; Kerbel RS
Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
[TBL] [Abstract][Full Text] [Related]
25. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
[TBL] [Abstract][Full Text] [Related]
26. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Cui T; Zhang S; Sun H
Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
[TBL] [Abstract][Full Text] [Related]
27. Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma.
Ni W; Li Z; Liu Z; Ji Y; Wu L; Sun S; Jian X; Gao X
J Pharm Sci; 2019 Mar; 108(3):1284-1295. PubMed ID: 30395829
[TBL] [Abstract][Full Text] [Related]
28. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
[TBL] [Abstract][Full Text] [Related]
29. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Zhang L; Gong F; Zhang F; Ma J; Zhang P; Shen J
Int J Nanomedicine; 2013; 8():1517-24. PubMed ID: 23620667
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
32. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Fernando J; Malfettone A; Cepeda EB; Vilarrasa-Blasi R; Bertran E; Raimondi G; Fabra À; Alvarez-Barrientos A; Fernández-Salguero P; Fernández-Rodríguez CM; Giannelli G; Sancho P; Fabregat I
Int J Cancer; 2015 Feb; 136(4):E161-72. PubMed ID: 25053293
[TBL] [Abstract][Full Text] [Related]
33. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L
J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
[TBL] [Abstract][Full Text] [Related]
34. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
35. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
[TBL] [Abstract][Full Text] [Related]
36. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
37. Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Thapa RK; Choi JY; Poudel BK; Hiep TT; Pathak S; Gupta B; Choi HG; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2015 Sep; 7(36):20360-8. PubMed ID: 26315487
[TBL] [Abstract][Full Text] [Related]
38. Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
Malarvizhi GL; Retnakumari AP; Nair S; Koyakutty M
Nanomedicine; 2014 Nov; 10(8):1649-59. PubMed ID: 24905399
[TBL] [Abstract][Full Text] [Related]
39. Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action.
Bahman AA; Abaza MSI; Khoushiash SI; Al-Attiyah RJ
Int J Mol Med; 2018 Sep; 42(3):1695-1715. PubMed ID: 29901131
[TBL] [Abstract][Full Text] [Related]
40. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]